FDA July Meeting May Ease Peptide Compounding Limits as RFK Jr. Pushes Access, Experts Warn of Safety Risks
Apr 20
Developing
3
The U.S. Food and Drug Administration has scheduled a July 2026 advisory committee meeting to consider easing limits on more than seven injectable peptides — including influencer-favored BPC-157 — by asking outside advisers whether those substances should be added to the list of compounds that state-licensed pharmacies may legally prepare. The agency also plans to remove those peptides from a restrictive "do not compound" list while it seeks outside guidance. The move comes amid public advocacy from Robert F. Kennedy Jr., who told Joe Rogan he is a "big fan" of peptides and said he wants improved access from "ethical suppliers," and it has prompted sharp warnings from former FDA officials who say loosening compounding rules could undercut drug-approval incentives and create safety risks.
